WallStSmart

CytomX Therapeutics Inc (CTMX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CytomX Therapeutics Inc generates 2367% more annual revenue ($18.30M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CTMX earns a higher WallStSmart Score of 33/100 (F).

CTMX

Avoid

33

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: -4.55

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CTMXSignificantly Overvalued (-77.1%)

Margin of Safety

-77.1%

Fair Value

$3.14

Current Price

$3.29

$0.15 premium

UndervaluedFair: $3.14Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTMX3 strengths · Avg: 9.3/10
EPS GrowthGrowth
60.6%10/10

Earnings expanding 60.6% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

CTMX4 concerns · Avg: 2.8/10
Market CapQuality
$716.89M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CTMX

The strongest argument for CTMX centers on EPS Growth, Debt/Equity, Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CTMX

The primary concerns for CTMX are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

CTMX carries more volatility with a beta of 2.14 — expect wider price swings.

CTMX is growing revenue faster at -92.4% — sustainability is the question.

CTMX generates stronger free cash flow (-18M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CTMX scores higher overall (33/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CytomX Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?